In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds

[1]  Y. Guan,et al.  Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings , 2004, Thorax.

[2]  Feng Chen,et al.  Application of high-speed counter-current chromatography to the preparative separation and purification of baicalin from the Chinese medicinal plant Scutellaria baicalensis. , 2003, Journal of chromatography. A.

[3]  X. L. Liu,et al.  Isolation and Characterization of Viruses Related to the SARS Coronavirus from Animals in Southern China , 2003, Science.

[4]  Hisashi Moriguchi,et al.  Treatment of SARS with human interferons , 2003, The Lancet.

[5]  Y. Guan,et al.  Early diagnosis of SARS Coronavirus infection by real time RT-PCR , 2003, Journal of Clinical Virology.

[6]  H. Doerr,et al.  Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus , 2003, The Lancet.

[7]  J. Peiris,et al.  Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study , 2003, The Lancet.

[8]  C. Fraser,et al.  Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong , 2003, The Lancet.

[9]  P. Raanani,et al.  Immune-Mediated Complications during Interferon Therapy in Hematological Patients , 2002, Acta Haematologica.

[10]  A. Khan,et al.  Interstitial pneumonitis in a patient treated with alpha-interferon and ribavirin for hepatitis C infection. , 2001, The American journal of the medical sciences.

[11]  Ji Ming Wang,et al.  Flavonoid baicalin inhibits HIV-1 infection at the level of viral entry. , 2000, Biochemical and biophysical research communications.

[12]  R. Price.  Artemisinin drugs: novel antimalarial agents , 2000, Expert opinion on investigational drugs.

[13]  M. Fukushima,et al.  Baicalin, an inhibitor of HIV-1 production in vitro. , 1998, Antiviral research.

[14]  H. Thomas,et al.  Different relative activities of human cell-derived interferon-alpha subtypes: IFN-alpha 8 has very high antiviral potency. , 1996, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[15]  K. Yagawa,et al.  Interferon-related bronchiolitis obliterans organizing pneumonia. , 1994, Chest.

[16]  M. Meltzer,et al.  Increased Efficacy of Human Natural Interferon α (IFN-αn3) Versus Human Recombinant IFN-α2 for Inhibition of HIV-1 Replication in Primary Human Monocytes , 1993 .

[17]  M. Lebwohl,et al.  Recombinant alpha-2 interferon gel treatment of recurrent herpes genitalis. , 1992, Antiviral research.

[18]  D. Isaacs,et al.  The efficacy of intranasal interferonα-2a in respiratory syncytial virus infection in volunteers , 1990, Antiviral Research.

[19]  L. Eron,et al.  Therapy of genital herpes with topically applied interferon , 1987, Antimicrobial Agents and Chemotherapy.

[20]  J. Albrecht,et al.  Prophylactic efficacy of intranasal alpha 2-interferon against rhinovirus infections in the family setting. , 1986, The New England journal of medicine.

[21]  F. Hayden,et al.  Intranasal Interferon-α2, Treatment of Experimental Rhinoviral Colds , 1984 .

[22]  D. Tyrrell,et al.  Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers , 1983, Antimicrobial Agents and Chemotherapy.

[23]  P. Neiman,et al.  Toxicity and efficacy of human leukocyte interferon for treatment of cytomegalovirus pneumonia after marrow transplantation. , 1980, The Journal of infectious diseases.

[24]  M. Meltzer,et al.  Increased efficacy of human natural interferon alpha (IFN-alpha n3) versus human recombinant IFN-alpha 2 for inhibition of HIV-1 replication in primary human monocytes. , 1993, AIDS research and human retroviruses.

[25]  F. Hayden,et al.  Intranasal interferon-alpha 2 treatment of experimental rhinoviral colds. , 1984, The Journal of infectious diseases.

[26]  of efficacy: , 2022 .